Anterior-Segment Applications

The anterior segment, the front of the eye, is the foundation of Espansione's platform and where its evidence base is strongest. This page summarises how light-based therapy is applied here and links to the conditions and tools involved.

The clinical territory

Anterior-segment applications centre on the ocular surface and the eyelids: dry eye disease, the meibomian gland dysfunction that drives most evaporative dry eye, the broader category of ocular surface disease, and lid-margin conditions such as blepharitis, Demodex blepharitis and ocular rosacea. Related problems include chalazion, styes, contact lens discomfort, digital eye strain and the ocular surface burden in Sjögren's and glaucoma.

Why light therapy fits here

Most anterior-segment disease is multifactorial, with patients carrying several drivers at once. LM™ LLLT photobiomodulation acts across the tear film, eyelids and ocular surface, which is why TFOS DEWS III recognises it across all three driver groups (TFOS DEWS III, 2025, American Journal of Ophthalmology). For the lid-driven, inflammatory component of severe cases, OPE™ IPL is added as an adjunct.

How it is delivered

Care begins with screening and diagnosis, often using the me-check® platform, and proceeds to treatment on eye-light® or meibomask®, with my-mask® for home maintenance. The supporting evidence is summarised under combined therapy and the publication library.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.